Project Name: Mid and South Essex NHS Foundation Trust Lipid Clinic

Project Summary:

The CWP is structured such that a multi-disciplinary health professional team will provide tailored care for patients, aligned with the Primary Care Network (PCN) Contract Direct Enhanced Service (DES) and the Locally defined Cardiovascular plans.

The main objective of the CWP is to improve the quality of care for patients and support the early identification, review, and medical optimization of patients with atherosclerotic cardiovascular disease (ASCVD), FH patients who are at high risk of cardiovascular events and other primary prevention where appropriate, who are not achieving lipid levels as specified in national and/or local guidance, in response to the needs of the CW Partner.  

Planned Milestones:

Collection of baseline data, in line with the above Project Outcome Measures & Data Collection table.

Confirmation of clinical and operational pathway, referral letter template to primary care, policy and protocol creation, and readiness to begin the clinical activity.

Confirmation of recruitment of band 7 nurse. 

Collection & submission of 3, 6, 9 and 12 months clinical activity data and Project Review meeting at 3,6,9 and 12 months to discuss project progress.

Submission of business case to continue the service offered by this project.

Analysis of CWP data, submission of Final Project Report, Submission of Outcomes Summary.

Expected Benefits:

Anticipated benefits for patients:

  • Improved access to lipid management care leading to optimal diagnosis and management of ASCVD treatments.   
  • Enhanced experience around ASCVD with ongoing management of the condition.   
  • Improved access to appropriate medication for CVD prevention as per National and local guidelines. 

Anticipated benefits for the organisations:

  • Increased proportion of ASCVD patients reviewed. 
  • Increased proportion of ASCVD patients receiving expert and timely review. 
  • Increased proportion of patients receiving guideline-directed pharmacotherapy. 
  • Support aligned to NHS Long Term Plan, CVDPREVENT, and Network Contract DES.

Anticipated Benefits for Novartis:

  • Insight on the appropriate use of ASCVD licensed medicines in line with NICE guidelines, including Novartis’s medicine.  
  • Enhanced reputation, and supporting Novartis’ vision that no patient should have to wait for an extraordinary life, by supporting high quality Collaborative Working with healthcare organisations which addresses the problem of health inequalities.   
  • Ethical, professional, and transparent relationship between Novartis and the Healthcare Organisation.    

Start Date & Duration: November 2023 for 15 months.